Roche is again tracking down counterfeits of some of its cancer meds in Europe after an importer in Germany discovered the fakes. In this case, it is counterfeit MabThera, sold as Rituxan in the U.S.
Is it possible to be just too clever when it comes to marketing? That is something that Actavis CEO Brent Saunders will find out now that his decision to stop making the original version of the Alzheimer's treatment Namenda has turned into a production pileup for the company.
A new survey released earlier this week said that more than half of the worldwide sales of animal health, diagnostics and pet food sales are generated from companies located along what is marketed as the Kansas City Animal Health Corridor.
Vetmedica will open a $28.7 million warehouse and packaging facility this week in St. Joseph, MO, where the Boehringer Ingelheim animal health unit is headquartered.
Eli Lilly is consolidating all of its animal enzyme manufacturing operations to the U.K. A spokesperson for the Indianapolis-based company has announced that it will now close an Elanco plant in Terre Haute, IN, as part of the move across the pond.
A Johnson & Johnson exercise in creative problem solving has paid off for doctors and patients who rely on its ovarian cancer drug Doxil, availability of which has been uncertain for years. Its Janssen unit has accumulated a significant supply after assuming manufacturing at Boehringer Ingelheim plant that otherwise was closed down at the end of the year.
One hundred Irish Pfizer jobs once tapped for chopping are now safe, and the company's off-patent meds, like Lipitor, are the saviors.
Sun Pharmaceutical, which has touted itself as having the skills to fix quality problems at Ranbaxy Laboratories, is recalling two more lots of an antidepressant. The recall is its third since its April announcement that it would buy its troubled competitor in a $3.2 billion deal.
GlaxoSmithKline is under pressure from not one, but two regulatory bodies to get problems under control at a flu vaccine plant in Canada. After the FDA handed the company a warning letter late last month, Health Canada now says the pharma giant has a month to lay out a plan for resolving issues there.
GlaxoSmithKline, responding to an FDA warning letter sent to the plant that produces its FluLaval and other influenza vaccines for the U.S. and Canada, said it expects to be on track to produce more than 30 million doses for the upcoming flu season. But the experience of other drugmakers suggests that even a small hiccup in producing a vaccine for a crucial cycle can be significant to a drugmaker's top and bottom lines.